Enzo Biochem Statistics
Total Valuation
Enzo Biochem has a market cap or net worth of 23.58 million. The enterprise value is -13.58 million.
| Market Cap | 23.58M |
| Enterprise Value | -13.58M |
Important Dates
The next estimated earnings date is Friday, June 13, 2025.
| Earnings Date | Jun 13, 2025 |
| Ex-Dividend Date | Nov 15, 2024 |
Share Statistics
Enzo Biochem has 52.40 million shares outstanding. The number of shares has increased by 3.81% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 52.40M |
| Shares Change (YoY) | +3.81% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 20.27% |
| Owned by Institutions (%) | 21.68% |
| Float | 36.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.81 |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.64 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.86 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.04 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -50.44 |
Financial Efficiency
Return on equity (ROE) is -12.94% and return on invested capital (ROIC) is -9.73%.
| Return on Equity (ROE) | -12.94% |
| Return on Assets (ROA) | -7.46% |
| Return on Invested Capital (ROIC) | -9.73% |
| Return on Capital Employed (ROCE) | -19.74% |
| Revenue Per Employee | 222,092 |
| Profits Per Employee | -162,687 |
| Employee Count | 136 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.30% in the last 52 weeks. The beta is 1.16, so Enzo Biochem's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -63.30% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 57.78 |
| Average Volume (20 Days) | 778,443 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.09 |
Income Statement
In the last 12 months, Enzo Biochem had revenue of 29.09 million and -21.31 million in losses. Loss per share was -0.41.
| Revenue | 29.09M |
| Gross Profit | 13.02M |
| Operating Income | -9.94M |
| Pretax Income | -7.60M |
| Net Income | -21.31M |
| EBITDA | -8.56M |
| EBIT | -9.94M |
| Loss Per Share | -0.41 |
Balance Sheet
The company has 40.30 million in cash and 3.14 million in debt, giving a net cash position of 37.16 million or 0.71 per share.
| Cash & Cash Equivalents | 40.30M |
| Total Debt | 3.14M |
| Net Cash | 37.16M |
| Net Cash Per Share | 0.71 |
| Equity (Book Value) | 46.62M |
| Book Value Per Share | 0.89 |
| Working Capital | 35.04M |
Cash Flow
In the last 12 months, operating cash flow was -14.96 million and capital expenditures -784,000, giving a free cash flow of -15.75 million.
| Operating Cash Flow | -14.96M |
| Capital Expenditures | -784,000 |
| Free Cash Flow | -15.75M |
| FCF Per Share | -0.30 |
Margins
Gross margin is 44.74%, with operating and profit margins of -34.15% and -73.25%.
| Gross Margin | 44.74% |
| Operating Margin | -34.15% |
| Pretax Margin | -26.12% |
| Profit Margin | -73.25% |
| EBITDA Margin | -29.44% |
| EBIT Margin | -34.15% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 25.32%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 25.32% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -3.81% |
| Shareholder Yield | 21.51% |
| Earnings Yield | -90.38% |
| FCF Yield | -66.78% |
Stock Splits
The last stock split was on October 21, 2004. It was a forward split with a ratio of 1.05.
| Last Split Date | Oct 21, 2004 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Enzo Biochem has an Altman Z-Score of -4.03. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.03 |
| Piotroski F-Score | n/a |